Catalytic Wealth RIA LLC Buys Shares of 1,575 Illumina, Inc. (NASDAQ:ILMN)

Catalytic Wealth RIA LLC purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,575 shares of the life sciences company’s stock, valued at approximately $216,000.

A number of other large investors have also recently modified their holdings of ILMN. Trivant Custom Portfolio Group LLC raised its stake in Illumina by 166.7% in the first quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock worth $27,000 after buying an additional 125 shares in the last quarter. Wetzel Investment Advisors Inc. purchased a new stake in Illumina in the fourth quarter valued at $37,000. Massmutual Trust Co. FSB ADV boosted its holdings in Illumina by 86.8% in the first quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock valued at $39,000 after purchasing an additional 132 shares during the last quarter. Gradient Investments LLC boosted its stake in shares of Illumina by 375.0% during the 4th quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock worth $40,000 after acquiring an additional 225 shares in the last quarter. Finally, MeadowBrook Investment Advisors LLC purchased a new stake in shares of Illumina during the 4th quarter worth about $42,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ILMN. Jefferies Financial Group initiated coverage on shares of Illumina in a research note on Monday, June 3rd. They issued a “hold” rating and a $115.00 price target on the stock. Royal Bank of Canada decreased their price target on shares of Illumina from $249.00 to $242.00 and set an “outperform” rating for the company in a research report on Monday, July 1st. Stephens reissued an “overweight” rating and issued a $170.00 price target on shares of Illumina in a research report on Wednesday, July 10th. Citigroup raised shares of Illumina from a “neutral” rating to a “buy” rating and set a $140.00 price objective for the company in a research report on Wednesday, July 10th. Finally, Barclays lifted their price objective on shares of Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a research report on Wednesday, April 10th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $158.57.

Illumina Trading Down 0.1 %

NASDAQ:ILMN traded down $0.12 during mid-day trading on Tuesday, reaching $117.49. 305,003 shares of the company were exchanged, compared to its average volume of 2,140,911. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $195.64. The company has a fifty day moving average of $109.60 and a 200 day moving average of $124.60. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.26.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.05 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The company’s revenue was down 1.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.08 EPS. As a group, equities analysts predict that Illumina, Inc. will post 1.38 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.